乙核酸酶抑制剂:更新的专利审查 (2017-2023)
Jamshed Iqbal1,2, Sehrish Bano2, Imtiaz Ali Khan2
1Institute of Intelligent Machines, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China.
Expert opinion on therapeutic patents
|October 26, 2024
概括
乙核酸酶调节细胞表面核酸,影响纤维化和癌症等疾病. 本综述分析了2017-2023年间的专利抑制剂,强调了它们在各种疾病中的治疗潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 细胞表面的酶称为ectonucleotidases,它能水解核酸,调节关键的病理生理过程.
- 核酸与P1和P2受体结合,影响炎症,纤维化,癌症和自身免疫性疾病.
- 调节ectonucleotidase活性为各种疾病提供治疗潜力.
研究的目的:
- 审查核核酸酶抑制剂的化学和临床应用.
- 为了分析2017年至2023年间开发的专利性ECTONUCLEOTIDASE抑制剂.
- 提供关于抑制ectonucleotidase的进展的见解,包括组合疗法和选择性.
主要方法:
- 对2017年至2023年期间提交的专利进行了全面分析.
- 对核核酸酶抑制剂的化学结构和临床用途的审查.
- 检查该领域最近的进展,如组合疗法和增强的选择性.
主要成果:
- 鉴定核酸/核酸相似物,非核酸相似物和双环化合物作为强效的核酸酶抑制剂.
- 专利分子及其治疗潜力的详细概述.
- 突出新兴趋势,如提高药物选择性和组合策略.
结论:
- 核酸酶抑制剂代表了涉及核酸信号传递的疾病的有前途的治疗策略.
- 最近的专利展示了抑制剂设计的进步,重点是特异性和有效性.
- 未来的方向包括探索组合疗法和新的分子支架,以提高治疗结果.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:20Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147